Phase III of Recombinant Human Activated Protein C and Low Dose of Hydrocortisone and Fludrocortisone in Adult Septic Shock (APROCCHS)

NCT00625209 Phase 3 COMPLETED

This study aims at comparing the efficacy and safety of recombinant human activated protein C to that of low dose of corticosteroids and at investigating the interaction between these drugs in the management of septic shock

Details

Lead sponsor	University of Versailles
Phase	Phase 3
Status	COMPLETED
Enrolment	1241
Start date	2008-03
Completion	2016-07

Conditions

• Septic Shock

Interventions

• placebos
• hydrocortisone and fludrocortisone and placebo
• recombinant human activated protein C and placebos
• recombinant human activated protein C and hydrocortisone and fludrocortisone

Primary outcomes

• 90-day mortality — 90 day

Countries

France